The notion that chronic kidney disease (CKD) can be repaired has spurred intense research over the past decade and has focused on antifibrotic therapies, with numerous strategies being explored preclinically and clinically. In this Review, the authors describe the therapeutic concepts and molecular targets under investigation to inhibit or even reverse CKD.
- Desiree Tampe
- Michael Zeisberg
